Markel Group Inc. Acquires 7,000 Shares of Thermo Fisher Scientific Inc. $TMO

Markel Group Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 62,800 shares of the medical research company’s stock after purchasing an additional 7,000 shares during the quarter. Markel Group Inc.’s holdings in Thermo Fisher Scientific were worth $36,389,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. High Note Wealth LLC increased its holdings in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 29 shares in the last quarter. JPL Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at approximately $28,000. Beacon Financial Strategies CORP purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Olistico Wealth LLC purchased a new position in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Cloud Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at approximately $31,000. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.2%

Shares of NYSE TMO opened at $448.55 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. The business’s fifty day moving average price is $480.25 and its 200-day moving average price is $538.17. The stock has a market capitalization of $166.69 billion, a PE ratio of 24.66, a P/E/G ratio of 1.99 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter in the prior year, the firm earned $5.15 EPS. The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.34%.

Insiders Place Their Bets

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total value of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on TMO. Citigroup lifted their target price on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Barclays cut their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 14th. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Finally, Royal Bank Of Canada set a $490.00 target price on Thermo Fisher Scientific and gave the company a “sector perform” rating in a research report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus price target of $616.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.